VanEck Pharmaceutical ETF (PPH) |
| 104.04 0.31 (0.3%) 04-14 16:00 |
| Open: | 103.39 |
| High: | 104.635 |
| Low: | 103.39 |
| Volume: | 151,560 |
| Market Cap: | 614(M) |
| PE Ratio: | 22.73 |
| Exchange: | NASDAQ Global Market |
| Industry: | Asset Management |
| Sector: | Financial Services |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 125.47 |
| Resistance 1: | 107.42 |
| Pivot price: | 103.23 |
| Support 1: | 102.96 |
| Support 2: | 100.20 |
| 52w High: | 112.58 |
| 52w Low: | 81.74 |
VanEck Pharmaceutical ETF (PPH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Thu, 02 Apr 2026
Should You Invest in the VanEck Pharmaceutical ETF (PPH)? - Yahoo Finance
Wed, 01 Apr 2026
VanEck Vectors Pharmaceutical ETF declares quarterly distribution of $0.8441 - MSN
Mon, 30 Mar 2026
Healthcare ETFs in Spotlight Amid Eli Lily's $2.8B AI Drug Move - TradingView — Track All Markets
Sat, 28 Mar 2026
PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026 - AOL.com
Sat, 28 Mar 2026
PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026 - 24/7 Wall St.
Mon, 02 Mar 2026
PPH, IHE, PJP: U.S. Pharmaceutical ETFs Offer Investors Innovation and Growth - TipRanks
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
